NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers

Journal of the National Cancer Institute

Volumn 105, Issue 1, 2013, Pages 11-24

  Lawrence, Yaacov Richard ^a,b   Vikram, Bhadrasain ^c   Dignam, James J ^e   Chakravarti, Arnab ^f   MacHtay, Mitchell ^g   Freidlin, Boris ^d   Takebe, Naoko ^h   Curran, Walter J ⁱ   Bentzen, Soren M ^j   Okunieff, Paul ^k   Norman Coleman, C ^d   Dicker, Adam P ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Division of Cancer Treatment and Diagnosis   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; MITOMYCIN; TEMOZOLOMIDE; TIRAPAZAMINE; TRASTUZUMAB; VORINOSTAT;

ABDOMINAL PAIN; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ANUS CANCER; BLADDER CANCER; BRAIN CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL PROLIFERATION; CHEMORADIOTHERAPY; CORRELATION ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; LUNG CANCER; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHARYNX CANCER; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSENSITIVITY; RADIOSENSITIZATION; RECTUM CANCER; REVIEW; SCREENING; STOMACH CANCER; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOSTATIC AGENTS; CYTOTOXINS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPAIR; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84872003539     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs472     Document Type: Review

References (129)

1. Harrington KJ, Billingham LJ, Brunner TB, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105(5):628-639.
2. Colevas AD, Brown JM, Hahn S, et al. Development of investigational radiation modifiers. J Natl Cancer Inst. 2003;95(9):646-651. (Pubitemid 36603720)
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987.
4. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009;92(1):4-14.
5. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6): 567.
6. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326(8):524-530.
7. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281(17):1623-1627. (Pubitemid 29211772)
8. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-730.
9. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709-715.
10. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348(9034):1049-1054.
11. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802-5812.
12. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 2009;337(5):295-300.
13. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-1488.
14. Bentzen S, Harari P, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Rev Clin Oncol. 2007;4(3):172-180. (Pubitemid 46358854)
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578. (Pubitemid 43209104)
16. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040-2048. (Pubitemid 350106711)
17. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525-1531.
18. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-1127.
19. Brown JM. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999;59(23):5863-5870. (Pubitemid 30004940)
20. Hoogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol (R Coll Radiol). 2007;19(6):385-396. (Pubitemid 47007426)
21. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol. 2004;14(3):233-240. (Pubitemid 38903227)
22. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol). 2007;19(6):427-442. (Pubitemid 46995614)
23. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066-4074. (Pubitemid 47492951)
24. Kallman RF, Dorie MJ. Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys. 1986;12(4):681-685. (Pubitemid 16081633)
25. Ang KK. More Lessons learned from the suffocation of hypoxia. J Clin Oncol. 2010;28(18):2941-2943.
26. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990;50(24):7745-7749.
27. Brown JM, Marilyn JL. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1991;20(3):457-461.
28. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02. 02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28(18):2989-2995.
29. Williamson SK, Crowley JJ, Lara PN, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-smallcell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005;23(36):9097- 9104.
30. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI. Exploring vascular dysfunction caused by tirapazamine. Microvasc Res. 2008;75(2):247-255. (Pubitemid 351240940)
31. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol. 2006;78(2):138-145. (Pubitemid 43344172)
32. Bains LJ, Baker JH, Kyle AH, Minchinton AI, Reinsberg SA. Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;74(3):957-965.
33. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410.
34. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11(10):1873-1878. (Pubitemid 23304610)
35. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350-7356. (Pubitemid 36025259)
36. Huang S-M, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6(6):2166-2174. (Pubitemid 30399181)
37. Klaus D, Claus M, Hans-Peter R. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005;76(2):157-161.
38. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18(suppl1): 47s-53.
39. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407. J Clin Oncol. 2011;29(23):3120-3125.
40. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93-99.
41. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28.
42. Giro C, Berger B, Bolke E, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009;90(2):166-171.
43. Glass C, Den R, Dicker AP, Lawrence YR. Toxicity of phase I radiation oncology trials: worldwide experience. Int J Radiat Oncol Biol Phys. 2010;78(3)(suppl.) :s65.
44. Goldie JH, Coldman AJ. Drug Resistance in Cancer: Mechanisms and Models. Cambridge, UK: Cambridge University Press; 2009.
45. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010;87(5):543-552.
46. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
47. Hait WN. Targeted cancer therapeutics. Cancer Res. 2009;69(4):1263-1267.
48. Heppner GH. Tumor heterogeneity. Cancer Res. 1984;44(6):2259-2265. (Pubitemid 14110633)
49. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxiainduced dedifferentiation of tumor cells-mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol. 2005;16(4-5): 554-563. (Pubitemid 41247879)
50. Linder S, Shoshan M. Is translational research compatible with preclinical publication strategies? Radiat Oncol. 2006;1:4.
51. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987-989. (Pubitemid 32937367)
52. Movsas B. Randomized trial of amifostine in locally advanced non-smallcell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin Oncol. 2005;23(10):2145-2154. (Pubitemid 46218706)
53. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol. 2001;19(3):792-799. (Pubitemid 32119095)
54. van Putten JWG, Price A, van der Leest AHD, Gregor A, Little FA, Groen HJM. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res. 2003;9(7):2472-2477. (Pubitemid 36842086)
55. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999;59(1):107-114. (Pubitemid 29062965)
56. Gregoire V, Beauduin M, Rosier JF, et al. Kinetics of mouse jejunum radiosensitization by 2', 2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Br J Cancer. 1997;76(10):1315-1321. (Pubitemid 27474973)
57. Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol. 2006;24(27):4426-4433. (Pubitemid 46630980)
58. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46(1):33-48. (Pubitemid 20245604)
59. Albani S, Prakken B. The advancement of translational medicine-from regional challenges to global solutions. Nat Med. 2009;15(9):1006-1009.
60. Borad MJ, Von Hoff DD. Clinical trial designs for more rapid proof-ofprinciple and approval. In: Neidel S, ed. Cancer Drug Design and Discovery. 1st ed. Waltham, MA: Academic Press; 2007:53-87.
61. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1-12. (Pubitemid 351287920)
62. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16(6):1745-1755.
63. Seymour L, Ivy SP, Sargent D, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1764-1769.
64. Forster MD, Saijo N, Seymour L, Calvert H. Performing phase I clinical trials of anticancer agents: perspectives from within the European Union and Japan. Clin Cancer Res. 2010;16(6):1737-1744.
65. Bates SE. Phase I clinical trials: overcoming barriers. Clin Cancer Res. 2010;16(6):1709.
66. Rock EP, Molloy VJ, Humphrey JS. GCP data quality for early clinical development. Clin Cancer Res. 2010;16(6):1756-1763.
67. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res. 2010;16(6):1710-1718.
68. Senderowicz AM. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer. Clin Cancer Res. 2010;16(6):1719-1725.
69. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the National Cancer Institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1726-1736.
70. Rosenstein BS, Held KD, Rockwell S, Williams JP, Zeman EM. American Society for Radiation Oncology (ASTRO) survey of radiation biology educators in U. S. and Canadian radiation oncology residency programs. Int J Radiat Oncol Biol Phys. 2009;75(3):896-905.
71. Wasserman TH, Smith SM, Powell SN. The growth of academic radiation oncology: a survey of endowed professorships in radiation oncology. Int J Radiat Oncol Biol Phys. 2009;74(2):338-340.
72. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66(20):10040-10047. (Pubitemid 44672057)
73. Jaboin JJ, Shinohara ET, Moretti L, Yang ES, Kaminski JM, Lu B. The role of mTOR inhibition in augmenting radiation induced autophagy. Technol Cancer Res Treat. 2007;6(5):443-447. (Pubitemid 47613293)
74. Shinohara E, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 2005;24(35):5414-5422. (Pubitemid 43080085)
75. Vikram B, Coleman CN, Deye JA. Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site. Oncology (Williston Park). 2009;23(4):380-385.
76. Maity A, Bernhard EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res. 2010;70(6):2141-2145.
77. FitzGerald TJ, Urie M, Ulin K, et al. Processes for quality improvements in radiation oncology clinical trials. Int J Radiat Oncol Biol Phys. 2008;71(1) (suppl. 1):S76.
78. Justin EB, Joachim Y. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review. Int J Radiat Oncol Biol Phys. 2009;73(2):492-498.
79. Morris SL, Beasley M, Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350(26):2713-2715.
80. Bydder S, Spry N. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350(26):2713-2715.
81. Crane CH, Ben-Josef E, Small W Jr. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350(26):2713-2715.
82. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98. 02). J Clin Oncol. 2005;23(1):79.
83. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15(8):2769-2779. (Pubitemid 27330002)
84. Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012;82(2):809-816.
85. Michael JZ, Didier C, Zvi F, et al. Long term tolerance of high dose threedimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85(11):2460-2468.
86. Delanian S, Porcher Rl, Rudant Jrm, Lefaix J-L. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol. 2005;23(34):8570-8579. (Pubitemid 46211498)
87. Choy H, Jain AK, Moughan J, et al. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2009;4(1):80-86.
88. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994;12(8):1527-1531. (Pubitemid 24244984)
89. Huang YJ, Wu YL, Xie SX, Yang JJ, Huang YS, Liao RQ. Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial. Chin Med J (Engl). 2007;120(6):458-462.
90. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade cliomas. J Clin Oncol. 2010;28(18):3048-3053.
91. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-1076.
92. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112(3):650-658. (Pubitemid 351186206)
93. Milano M, Constine L, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol. 2008;3(1):36.
94. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8(2):89-91. (Pubitemid 41132735)
95. Acker JC, Marks LB, Spencer DP, et al. Serial in vivo observations of cerebral vasculature after treatment with a large single fraction of radiation. Radiat Res. 1998;149(4):350-359. (Pubitemid 28150928)
96. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
97. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71(7):2488-2496.
98. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931.
99. Brown A, Wendler D, Camphausen K, Miller F, Citrin D. Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J Clin Oncol. 2008;26(24):3987-3994.
100. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. 2008;100(17):1204-1214.
101. Sargent DJ, Goldberg RM. A flexible design for multiple armed screening trials. Stat Med. 2001;20(7):1051-1060.
102. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res. 2010;16(6):1710-1718.
103. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995;14(11):1149-1161.
104. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177-1182.
105. Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol. 2006;24(27):4426-4433. (Pubitemid 46630980)
106. Polley MY. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and lateonset toxicities. Stat Med. 2011;30(17):2130-2143.
107. Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol. 2010;5(7):932-934.
108. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer. 2009;45(2):275-280.
109. Seymour L, Ivy SP, Sargent D, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010;16(6):1764-1769.
110. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol. 2009;27(19):3073-3076.
111. Liu PY, LeBlanc M, Desai M. False positive rates of randomized phase II designs. Control Clin Trials. 1999;20(4):343-352. (Pubitemid 29320023)
112. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69(12):1375-1381. (Pubitemid 16163075)
113. Steinberg SM, Venzon DJ. Early selection in a randomized phase II clinical trial. Stat Med. 2002;21(12):1711-1726. (Pubitemid 34678902)
114. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23(28):7199-7206.
115. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010;28(11):1936-1941.
116. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011;103(14):1093-1100.
117. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997;350(9072): 161-165. (Pubitemid 27303621)
118. Zelen M. Play the winner rule and the controlled clinical trial. J Am Stat Assoc. 1969;64(325):131-146.
119. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011;29(6):606-9.
120. Korn EL, Freidlin B. Outcome-adaptive randomization: is it useful? J Clin Oncol. 2011;29(6):771-776.
121. Korn EL, Freidlin B. Reply to Y. Yuan et al. J Clin Oncol. 2011;29(13):e393.
122. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res. 2008;14(14): 4368-4371.
123. Schaid DJ, Wieand SAM, Therneau TM. Optimal two-stage screening designs for survival comparisons. Biometrika. 1990;77(3):507-513.
124. Mandrekar SJ, Sargent DJ. All-comers versus enrichment design strategy in phase II trials. J Thorac Oncol. 2011;6(4):658-660.
125. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res. 2004;10(20):6759-6763. (Pubitemid 39383023)
126. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102(3):152-160.
127. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7(1): 33-47.
128. Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. Pharmacogenomics. 2010;11(12):1679-1682.
129. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.